Thrasos is a private, clinical-stage, biotherapeutics company focused on the discovery and development of targeted therapies for the prevention and treatment of kidney disease. The Company is focused on two key areas of unmet need: acute kidney injury (AKI), for which THR-184 is in clinical development and a preclinical program for chronic kidney disease (CKD). Thrasos’ drug candidates have been shown to protect, repair and restore cell and tissue function in the kidney and other organs.
 
 
© 2013 Thrasos Innovation, Inc. All rights reserved.